Furthermore, PSMA-targeted PET/CT revealed higher tumor uptake and a more considerable tumor boundary than [18F]FDG PET/CT, which may be a potential further advantage over metabolic imaging [14,17,19]. The gene discussed is FOLH1; the disease is neoplasm.